期刊
BONE MARROW TRANSPLANTATION
卷 46, 期 3, 页码 385-392出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2010.115
关键词
AML; autologous HCT; overall survival; relapse; relative mortality
资金
- Public Health Service, National Cancer Institute (NCI) [U24-CA76518]
- Public Health Service, National Heart, Lung and Blood Institute (NHLBI) [U24-CA76518]
- Public Health Service, National Institute of Allergy and Infectious Diseases (NIAID) [U24-CA76518]
- NHLBI [5U01HL069294]
- NCI [5U01HL069294]
- Health Resources and Services Administration (HRSA/DHHS) [HHSH234200637015C]
- Office of Naval Research [N00014-06-1-0704, N00014-08-1-0058]
- AABB
- Aetna
- American Society for Blood and Marrow Transplantation
- Amgen, Inc
- Astellas Pharma US, Inc
- Baxter International, Inc
- Bayer HealthCare Pharmaceuticals
- Be the Match Foundation
- Biogen IDEC
- BioMarin Pharmaceutical, Inc
- Biovitrum AB
- BloodCenter of Wisconsin
- Blue Cross and Blue Shield Association
- Bone Marrow Foundation
- Canadian Blood and Marrow Transplant Group
- CaridianBCT
- Celgene Corporation
- CellGenix, GmbH
- Centers for Disease Control and Prevention
- Children's Leukemia Research Association
- ClinImmune Labs
- CTI Clinical Trial and Consulting Services
- Cubist Pharmaceuticals
- Cylex Inc
- CytoTherm
- DOR BioPharma, Inc
- Dynal Biotech, an Invitrogen Company
- Eisai, Inc
- Enzon Pharmaceuticals, Inc
- European Group for Blood and Marrow Transplantation
- Gamida Cell, Ltd
- GE Healthcare
- Genentech, Inc
- Genzyme Corporation
- Histogenetics, Inc
- HKS Medical Information Systems
- Hospira, Inc
- Infectious Diseases Society of America
- Kiadis Pharma
- Kirin Brewery Co., Ltd
- Leukemia & Lymphoma Society
- Merck Company
- Medical College of Wisconsin
- MGI Pharma, Inc
- Michigan Community Blood Centers
- Millennium Pharmaceuticals, Inc
- Miller Pharmacal Group
- Milliman USA, Inc
- Miltenyi Biotec, Inc
- National Marrow Donor Program
- Nature Publishing Group
- New York Blood Center
- Novartis Oncology
- Oncology Nursing Society
- Osiris Therapeutics, Inc
- Otsuka America Pharmaceutical, Inc
- Pall Life Sciences
- Pfizer Inc
- Saladax Biomedical, Inc
- Schering Corporation
- Society for Healthcare Epidemiology of America
- StemCyte, Inc
- StemSoft Software, Inc
- Sysmex America, Inc
- Teva Pharmaceutical Industries
- THERAKOS, Inc
- Thermogenesis Corporation
- Vidacare Corporation
- Vion Pharmaceuticals, Inc
- ViraCor Laboratories
- ViroPharma, Inc
- Wellpoint, Inc
We describe the long-term outcomes of autologous hematopoietic cell transplantation (HCT) for 315 AML patients in first or second complete remission (CR). All patients were in continuous CR for >= 2 years after HCT. Patients were predominantly transplanted in CR1 (78%) and had good or intermediate cytogenetic risk disease (74%). Median follow-up of survivors was 106 (range, 24-192) months. Overall survival at 10 years after HCT was 94% (95% confidence intervals, 89-97%) and 80% (67-91%) for patients receiving HCT in CR1 and CR2, respectively. The cumulative incidence of relapse at 10 years after HCT was 6% (3-10%) and 10% (3-20%) and that of nonrelapse mortality was 5% (2-9%) and 11% (4-21%), respectively. On multivariate analysis, HCT in CR2 (vs CR1), older age at transplantation and poor cytogenetic risk disease were independent predictors of late mortality and adverse disease-free survival. The use of growth factors to promote engraftment after HCT was the only risk factor for relapse. Relative mortality of these 2-year survivors was comparable to that of age-, race- and gender-matched normal population. Patients who receive autologous HCT for AML in CR1 or CR2 and remain in remission for >= 2 years have very favorable long-term survival. Their mortality rates are similar to that of the general population. Bone Marrow Transplantation (2011) 46, 385-392; doi:10.1038/bmt.2010.115; published online 17 May 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据